• Must have given written informed consent (signed and dated) and any authorizations required by local law.

• Male or female with a definitive diagnosis of primary biliary cholangitis (PBC).

• Ursodeoxycholic acid (UDCA) for the past 12 months (stable dose for \>3 months prior to screening) or intolerant to UDCA (last dose of UDCA \>3 months prior to screening).

• Laboratory parameters measured by the Central Laboratory at screening:

‣ Alkaline phosphatase (ALP) ≥1.67× ULN (upper limit of normal)

⁃ Aspartate aminotransferase (AST) ≤3× ULN

⁃ Alanine aminotransferase (ALT) ≤3× ULN

⁃ Total bilirubin ≤2× ULN

⁃ Estimated glomerular filtration rate (eGFR) \>45 mL/min/1.73 m\^2 (calculated by the Modification of Diet in Renal Disease study equation).

⁃ International normalized ratio (INR) below 1.1× ULN (For individuals on anticoagulation therapy, INR must be maintained in the range required for prophylaxis for their specific disease).

⁃ Platelet count ≥100 ×10\^3/µL.

• Females of reproductive potential must use at least 1 barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male individuals who are sexually active with female partners of reproductive potential must use barrier contraception, and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose.